CDRI’s new research hub in Lucknow to facilitate innovation in drug discovery & development

Lucknow:  Marking 70 years of its inception, the Central Drug Research Institute (CDRI) in Lucknow launched a new and advanced research facility called Common Research and Technology Development Hub (CRTDH). As per the motive behind its establishment, this centre would be aiding hospitals and pharmaceutical sector entities in conducting clinical tests and trials. Besides, the latest hub would also facilitate MSMEs and academia with an avenue for high-level research.

The representative from CDRI was quoted saying “CRDTH is not only for scientists but for institutions conducting advanced research in the field of drug discovery. CDRI will not only provide infrastructure support like high-end laboratories and equipment but also the expertise of our scientists.”

With the cutting edge research and development projects undertaken by the CSIR-CDRI, the world has been gifted with a wide range of low-cost efficient drugs and medicines. Amongst its innovative contributions to the drug industry, the most prominent names are Centchroman, the first non-steroidal oral contraceptive and Arteether, a lifesaving drug for cerebral malaria.

In addition to being a top-notch organisation for the development and manufacturing of drugs, CDRI has worked on multiple initiatives to upgrade the quality of elementary research and strengthen human resources.

The CRTDH was inaugurated along with the launch of Atal National Colloquium on Healthcare and Innovation. As a part of this flagship program, a number of renowned and eminent personalities will hold sessions and lectures. This program has been planned to honour the erstwhile Prime Minister Atal Vihari Bajpayee’s vision, that considered scientific development, the topmost priority. This event was also marked by the announcement of the coveted CDRI Awards-2021 for Excellence in Drug Research.

Related Posts

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

New Delhi: The entry of semaglutide generics in India is ‘stimulating’ market growth and providing a favourable push to Eli Lilly’s blockbuster brand Mounjaro (tirzepatide), said Patrik Jonsson, Executive Vice…

Pak-made illegal cosmetics recovered from Itwari shop

Nagpur: Maharashtra Food and Drug Administration (FDA), Nagpur Division, raided a cosmetics firm in Itwari market and seized Pakistan-origin beauty products suspected to have harmful mercury and steroids last week. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

You Missed

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Semaglutide generics ‘stimulating’ Obesity market growth, says Eli Lilly’s Patrik Jonsson

Pak-made illegal cosmetics recovered from Itwari shop

Pak-made illegal cosmetics recovered from Itwari shop

Licences of 20 medical stores suspended after inspections

Licences of 20 medical stores suspended after inspections

Bain Capital sells nearly 1 pc stake in Emcure Pharma for Rs 289 crore

Bain Capital sells nearly 1 pc  stake in Emcure Pharma for Rs 289 crore

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

Sun Pharma to acquire U.S. firm Organon in $11.75 billion deal

HP accounts for 47 inferior drugs in March alert

HP accounts for 47 inferior drugs in March alert